usa flag
NASDAQ:PTPI
SPONSORED

A Transformative Treatment In This $3.2 Billion Market(1) Has Helped Petros Pharmaceuticals’ Sales Skyrocket 300%(2)

July 12, 2021

Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021

The Top 5 Potential Drivers For Petros Pharmaceuticals U.S. NASDAQCM: (PTPI)

  1. Petros Pharmaceutical’s flagship asset STENDRA has already seen success in an erectile dysfunction market expected to become a $3.2 billion industry by 2022.(1) Approximately 30 million men in the US suffer from erectile dysfunction, and only 25% are estimated to have sought treatment.(3)
  2. STENDRA saw a 300% increase in net sales during the first quarter of 2021 vs. the first quarter of 2020. Tablet prescriptions also increased 23% year-over-year and 6% over the prior quarter, achieving a record high in prescription tablets.(2)
  3. Petros may have the first FDA-approved topical therapy for Peyronie’s disease in its pipeline.(3)
  4. Peyronie’s disease, an unpleasant condition that currently affects about 11 million men in the U.S., could be a $1.0 billion market.(3)
  5. Over the last 4 months, the PTPI stock touched a low of roughly $2.69 a share on Mar 5, 2021.(4) It then promptly skyrocketed approximately 65.43% to its May 17, 2021 peak of $4.45. Afterward, the stock traded as low as $2.82 on May 17, 2021, yet rallied as much as 40.43% to its Jun 22, 2021 price of $3.96.(4)
  6. Petros’s leadership has extensive experience in the biopharmaceutical industry, including Chairman John Shulman and Board Member Greg Bradley, who together brought Plan B One-Step from a prescription-only drug to an OTC product, driving the #1 selling SKU in the U.S.(3)

Somewhere between a once-in-a-century type of health situation and political squabbling, we forgot something. The Men’s Health market is massive, underserved, and in constant demand.

Think about these figures. Approximately 30 million men in the US suffer from erectile dysfunction, and only 25% are estimated to have sought treatment.(3) This market’s expanding too. 1 in 4 ED patients are under the age of 40(3) in a market that worldwide is expected to become a $3.2 billion industry by 2022, according to a new report by Grand View Research Inc.(1) This is due to a “rising adoption of a sedentary lifestyle and increasing prevalence of conditions causing erectile dysfunction such as stress, hypertension, and related medications.”(1)

Then there’s Peyronie’s disease, an unpleasant condition that currently affects about 11 million men in the U.S. But what if I told you that this disease market, worth potentially $1.0 billion, has no current FDA-approved topical therapies?(1) Or what if I said that the only current treatment options consist of a series of injections, invasive surgeries, or devices?(1)

If that’s your idea of a good time, I’m never partying with you.

Fortunately, Petros Pharmaceuticals U.S. NASDAQCM: (PTPI) may have the most cutting-edge solutions for both conditions.

Petros’s flagship asset, STENDRA, has been so promising with treating erectile dysfunction that its sales skyrocketed 300% during the first quarter of 2021 vs. the first quarter of 2020.(2) Not to mention, the very first FDA-approved topical therapy for early phase Peyronie’s disease could be right in Petros’s pipeline.(3)

Soaring Sales and Bullish Potential For Petros Pharmaceuticals U.S. NASDAQCM: (PTPI) 

Over the last 4 months, the PTPI stock touched a low of roughly $2.69 a share on Mar 5, 2021.(4) It then promptly skyrocketed approximately 65.43% to its May 17, 2021 peak of $4.45. Afterward, the stock traded as low as $2.82 on May 17, 2021, yet rallied as much as 40.43% to its Jun 22, 2021 price of $3.96.(4) The stock has experienced several peaks and valleys over the last few months, but the breakouts have been undeniable. After all, this is what tends to happen with stocks like PTPI with a float of about 6.18M.(5)

Get this, though. Several things are working in the company’s favor, indicating we could potentially be at the start of another significant breakout.

First and foremost, coupled with the stock’s small float, it has a very tightly held share structure, with approximately 36.74% of shares held by insiders and roughly 9.66% held by institutions.(5)

Most importantly, the company reported blowout earnings and growth for the quarter ended Mar 31, 2021. Highlights included the following:(2)

  • 300% increase in its flagship dr-ug STENDRA’s net sales during the first quarter of 2021 vs. the first quarter of 2020.
  • STENDRA tablet prescriptions increased 23% year-over-year and 6% over the prior quarter, achieving an all-time high in prescription tablets since Petros began marketing STENDRA.
  • Petros’s gross margins expanded to 84% in the first quarter of 2021, up from 56% in the same period of 2020.
  • Reduced operating expenses (excluding depreciation and amortization) to $3.9 million, down from $5 million in the first quarter of 2020, an improvement of 22%.
  • Positive quarterly net income was $3.0 million versus negative $6.1 million for the year-ago period due to increased net sales and margins, lower operating expenses, and a change in fair value of the derivative liability.

“Petros’s performance during the first quarter of 2021 significantly outpaced the same period from 2020, a [health predicament] comparator that provides us reason for optimism going into the rest of 2021 after a significant sector-wide downturn during the majority of 2020.  The Company enjoyed a 300% increase in STENDRA net sales year-over-year and prescriptions increased both year-over-year and over Q4 2020 – an all-time high since Petros began marketing STENDRA.  We believe this, in part, results from our streamlining of internal processes and cost-cutting measures, combined with implementing improved sales and marketing initiatives.  In addition, the Company enjoyed an emerging post-[health predicament] optimism from prescribers, consumers and distribution channels, which created a favorable environment for increased prescriptions,“ stated Fady Boctor, Petros Pharmaceuticals’ President and Chief Commercial Officer.(2)

Who Exactly Is Petros Pharmaceuticals U.S. NASDAQCM: (PTPI)?

Petros Pharmaceuticals U.S. NASDAQCM: (PTPI) is a Men’s Health pharmaceutical company. It aims to develop complementary therapeutics designed for a man’s journey, often centered around the ones he loves and lives for. The goal of Petros is to revolutionize the art and science behind the way men approach their health, by emphasizing the critical elements of medication adherence, tolerability, preservation of organic function, and vitality restoration.

Each element is approached within an integrated and interdependent perspective, targeting tangible enhancements to their health outcomes. Ultimately, Petros seeks to establish new foundations to Men’s Health that center around the whole of a man’s life and function.

Petros Pharmaceuticals was founded upon its first and currently commercialized Men’s Health therapeutic, a distinct molecule in erectile dysfunction, to continue awareness, education, and therapeutic value to the Men’s sexual dysfunction landscape.

In a continued effort to expand its portfolio into other underserved segments, Petros Pharmaceuticals has recently executed a definitive global exclusive licensing agreement for a novel and patented topical formulation candidate to treat Peyronie’s disease, a $1 billion market. This novel, topical formulation for treating acute Peyronie’s disease (PD) is currently undergoing early clinical testing. If approved, it would become the first and only clinically proven topical, non-invasive treatment for acute PD and a landmark achievement in men’s health.(3)

Today, Petros is actively researching new formulations across several serious men’s health conditions and plans to continue to build up its broader portfolio and pipeline.

STENDRA- Petros Pharmaceuticals’s U.S. NASDAQCM: (PTPI) Flagship Asset

STENDRA is Petros’s flagship asset and has already shown success in treating erectile dysfunction. This dr-ug is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction. It is distinct and patent-protected, and sales are soaring. As we mentioned before, in Petros’ latest quarterly report, the company announced a 300% increase in net sales from the same quarter a year ago. Tablet prescriptions also rose 23% year-over-year and 6% over the prior quarter, achieving an all-time high in prescription tablets since the dr-ug started being marketed.(2)

This may only be the start. The company intends to seek a new frontier supporting greater consumer reach, control, access and explore OTC or non-prescription designation potential with the FDA.(3)

Petros Pharmaceuticals’s U.S. NASDAQCM: (PTPI) Other Assets and Pipeline

Based on the success that STENDRA has had thus far, Petros is branching out with other dr-ug candidates to treat a myriad of Men’s Health conditions.

First, the company has its Timm Medical Device Business Unit Portfolio, which is currently in the market and generating sales revenue. This portfolio contains the Osbon ErecAid Vacuum Erection Device (VED) and the PostVac Vacuum Erection Device (VED).

Furthermore, Petros has a cutting-edge dr-ug in its pipeline that could be revolutionary. So much so that it could be on the cusp of being the first FDA-approved topical therapy for early phase Peyronie’s disease.(3)

This investigational topical compound for early Phase Peyronie’s disease is in the midst of one small double-blind pilot study conducted with statistically significant improvements in intended endpoints. A specific use designation concept within Peyronie’s disease is currently under review by the FDA, with a Pre-IND meeting to follow for the official clinical development roadmap.(3)

Petros Pharmaceuticals’s U.S. NASDAQCM: (PTPI) Game-Changing Strategic Alliances and More

Petros Pharmaceuticals and their strategic alliances are committed, well-equipped, and experienced in establishing new pathways for engaging the patient consumer to take control of their healthcare.

These options include NSURE (FDA), prescription to over-the-counter (OTC) switch (subject to FDA guidance and approval), and other emerging technology that supports nonprescription mechanisms.

Petros has several relationships to help drive success. The support consists of strong financial and strategic alliances that share a commitment to advancing the men’s health marketplace. Specifically, Petros’s Chairman John Shulman and Board Member Greg Bradley together brought Plan B One-Step from a prescription-only drug to an over-the-counter product, driving the #1 selling SKU in the U.S.(3)

Strong Leadership, Strong Results — Petros Pharmaceuticals U.S. NASDAQCM: (PTPI)

The Petros leadership team hosts extensive experience in the biopharmaceutical industry with expertise in successful clinical development programs, regulatory approvals, commercial launches, and enduring market-leading innovations; many of which were in the Men’s Health marketplace.

This executive team may also solidify the long-term portfolio aspirations of the organization, with late-stage innovative therapies intended to treat underserved, misunderstood, and largely unaddressed Men’s Health conditions.

Fady Boctor – President, Chief Commercial Officer

Mr. Boctor has over 20 years of experience in the pharmaceutical industry across various functions, including brand and portfolio marketing, sales channel optimization, product portfolio strategy development, and new product launches. Mr. Boctor has driven significant revenue growth for specialty biologics, mainstream Men’s Health product lines, rare/orphan disease therapeutics, and substance abuse rescue modalities. Mr. Boctor has worked for companies such as Novartis, Forest Pharmaceuticals, Auxilium Pharmaceuticals, Endo Pharmaceuticals, and Adapt Pharmaceuticals (Emergent Biosolutions). Mr. Boctor has his BA in International Relations from Hamline University, Masters in Diplomacy from Norwich University, and his MBA from the University of Manchester Business School.

Mitch Arnold – VP of Finance, Chief Accounting Officer

Robert Weinstein – Interim Chief Financial Officer

Andy Gesek – President of Timm Medical Technologies (subsidiary of Petros Pharmaceuticals)

Mr. Gesek brings over 20 years of diverse commercial and financial experience in the pharmaceutical industry. After starting his career in finance at Janssen Pharmaceutical, Mr. Gesek transitioned to pharmaceutical sales and has worked in areas that include: finance, sales, sales operations, forecasting, commercial valuation analytics, business development, and corporate strategy in companies including Janssen, Novartis, Pharmacia & Upjohn, Wyeth, Pfizer, Endo, and BTG. Before taking on his role at Timm Medical, Mr. Gesek served as Vice President, Commercial Operations and Business Strategy & General Manager, Established Brands Portfolio for Endo Pharmaceuticals. Here he worked closely with the President of the Branded Pharmaceuticals business to set, measure, and refine the strategy for the business unit leading a team of 20 who provided operational support to the company. Mr. Gesek is a graduate of Drexel and the Wharton School of Business.

Board of Directors

John Shulman – Executive Chairman of the Board

John Shulman is the Founder and Managing Partner of Juggernaut Capital Partners, a leading private equity firm with over $1 billion in committed capital. Mr. Shulman currently serves on the Boards of Directors of Metuchen Pharmaceuticals (Rx Pharmaceuticals) and Foundation Consumer Healthcare (OTC Pharmaceuticals). Previously, he served on the Boards of Directors of Triax Pharmaceuticals (Rx Pharmaceuticals) and Insight Pharmaceuticals (OTC Pharmaceuticals).

Mr. Shulman holds a B.S. degree in Finance from The McIntire School of Commerce at the University of Virginia.

Josh Silverman – Vice-Chairman of the Board

Mr. Silverman is the Co-founder and Managing Member of Parkfield Funding LLC. He is also a former Principal and Managing Partner of Iroquois Capital Management, LLC. Mr. Silverman served as Co-Chief Investment Officer of Iroquois from 2003 until July 2016. From 2000 to 2003, Mr. Silverman served as Co-Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Before forming Iroquois, Mr. Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as Assistant Press Secretary to The President of The United States. Mr. Silverman received his B.A. from Lehigh University in 1992. In the past five years, Mr. Silverman has served as a director at MGT Capital Investments, Inc. and National Holdings Corporation.

Greg Bradely – Board of Directors

Wayne Walker – Board of Directors

Mr. Walker founded Walker Nell Partners, Inc. (“Walker Nell”), a financial advisory firm, in 2013, where he continues to serve as the managing partner. Walker Nell provides corporate governance and restructuring advisory services, fiduciary services, litigation support, and other services to client corporations and law firms. In his role at Walker Nell, he has served on several private company boards. He currently serves as Chairman of the Board of Trustees of the National Philanthropic Trust. This public charity holds over $6 billion of assets under management. Mr. Walker has more than 25 years of experience in corporate law and corporate restructuring, including working 15 years at the DuPont Company.

Bruce Bernstein – Board of Directors

Bruce T. Bernstein has over thirty years of experience in the securities industry, primarily as a senior portfolio manager for two alternative finance funds and a deep understanding of the trading and structuring of arbitrage strategies. Since 2006, Mr. Bernstein has served as President of Rockmore Capital, LLC, a direct investment and lending fund. Previously, Bruce served as Co-President of Omicron Capital, LP, an investment firm based in New York. Before joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he served as a Senior Vice President in the bank’s Global Securities Arbitrage business unit and then President in charge of the bank’s proprietary investment business in the United States. Mr. Bernstein also serves as a member of the board of directors of XpresSpa Holdings, the leading airport spa company in the world. Mr. Bernstein is also a member of the board of Summit Digital Health, a laser-based blood glucose monitor distributor. Mr. Bernstein holds a B.B.A. from City University of New York (Baruch).

The Top 5 Potential Drivers For Petros Pharmaceuticals U.S. NASDAQCM: (PTPI)

  1. Petros Pharmaceutical’s flagship asset STENDRA has already seen success in an erectile dysfunction market expected to become a $3.2 billion industry by 2022.(1) Approximately 30 million men in the US suffer from erectile dysfunction, and only 25% are estimated to have sought treatment.(3)
  2. STENDRA saw a 300% increase in net sales during the first quarter of 2021 vs. the first quarter of 2020. Tablet prescriptions also increased 23% year-over-year and 6% over the prior quarter, achieving a record high in prescription tablets.(2)
  3. Petros may have the first FDA-approved topical therapy for Peyronie’s disease in its pipeline.(3)
  4. Peyronie’s disease, an unpleasant condition that currently affects about 11 million men in the U.S., could be a $1.0 billion market.(3)
  5. Over the last 4 months, the PTPI stock touched a low of roughly $2.69 a share on Mar 5, 2021.(4) It then promptly skyrocketed approximately 65.43% to its May 17, 2021 peak of $4.45. Afterward, the stock traded as low as $2.82 on May 17, 2021, yet rallied as much as 40.43% to its Jun 22, 2021 price of $3.96.(4)
  6. Petros’s leadership has extensive experience in the biopharmaceutical industry, including Chairman John Shulman and Board Member Greg Bradley, who together brought Plan B One-Step from a prescription-only drug to an OTC product, driving the #1 selling SKU in the U.S.(3)
Source 1: https://bit.ly/2SYTQ94
Source 2: https://irdirect.net/prviewer/release_only/id/4736722
Source 3: https://s3.amazonaws.com/cdn.irdirect.net/PIR/1436/5237/Petros_Corporate_Presentation_NobleCon_Jan_2021_1.pdf
Source 4: https://finance.yahoo.com/quote/PTPI/history?p=PTPI
Source 5: https://finance.yahoo.com/quote/PTPI/key-statistics?p=PTPI
Source 6: https://stockcharts.com/h-sc/ui?s=PTPI&p=D&yr=0&mn=4&dy=0&id=p77295025028&a=978841407&listNum=3

Legal Disclaimer-


Company Contact

Address: 1185 Avenue of the Americas 3rd Floor New York NY 10036 US
Phone: +1 973 242-0005
Website: https://www.petrospharma.com

Company Description

Petros Pharmaceuticals Inc is a men’s health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues including erectile dysfunction, peyronie’s disease, hormone health and substance use disorders. The company’s operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie’s disease.